Certara, Inc. (NASDAQ:CERT) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP cut its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 52.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 78,816 shares of the company's stock after selling 87,470 shares during the quarter. Bridgewater Associates LP's holdings in Certara were worth $923,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its position in Certara by 6.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 58,899 shares of the company's stock valued at $1,054,000 after purchasing an additional 3,639 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Certara by 2.9% in the 1st quarter. Janus Henderson Group PLC now owns 127,399 shares of the company's stock valued at $2,279,000 after acquiring an additional 3,578 shares during the last quarter. SG Americas Securities LLC purchased a new position in Certara in the second quarter worth about $226,000. Blue Trust Inc. bought a new stake in Certara during the second quarter worth approximately $26,000. Finally, Louisiana State Employees Retirement System raised its position in Certara by 2.3% during the second quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company's stock valued at $751,000 after purchasing an additional 1,200 shares during the period. Institutional investors own 73.96% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CERT. Barclays dropped their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday, November 7th. Robert W. Baird dropped their price objective on shares of Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, November 5th. Finally, UBS Group raised shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a research note on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $15.92.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company's stock, valued at approximately $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares in the company, valued at $552,503.73. The trade was a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Certara Stock Up 0.7 %

Shares of NASDAQ:CERT traded up $0.08 during trading hours on Monday, hitting $11.29. The company's stock had a trading volume of 2,044,888 shares, compared to its average volume of 805,984. The firm's fifty day moving average price is $10.81 and its 200 day moving average price is $12.98. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -56.45, a P/E/G ratio of 5.67 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.06 earnings per share. As a group, research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.